Obesity drugmakers Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) have found themselves in two contrasting positions as Robert F. Kennedy Jr., a leading critic of weight loss drugs, takes the helm of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback